Skip to main content
. Author manuscript; available in PMC: 2022 Jul 4.
Published in final edited form as: Cancer Genet. 2022 Mar 16;264-265:50–59. doi: 10.1016/j.cancergen.2022.03.001

Fig. 3.

Fig. 3.

Framework for assessing oncogenicity of NTRK fusions. Three primary specification categories (fusion gene structure, cancer association, and functional evidence) and a decision support framework is presented to classify fusions based on varying strengths of evidence into three tiers of oncogenicity: oncogenic, likely oncogenic, and unknown functional significance.